menu
    • menu
    [{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"House Dust Mite Allergen Extracts","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Stallergenes Greer \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Stallergenes Greer \/ Not Applicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Allergen Extract","moa":"IL-4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Stallergenes Greer \/ ","highestDevelopmentStatusID":"12","companyTruncated":"Stallergenes Greer \/ "},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Birch Pollen Extract","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Stallergenes Greer \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Not Applicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Stallergenes Greer","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Divestment","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Stallergenes Greer \/ Stallergenes Greer","highestDevelopmentStatusID":"12","companyTruncated":"Stallergenes Greer \/ Stallergenes Greer"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Stallergenes Greer \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Stallergenes Greer \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Stallergenes Greer

    Menu

    Stallergenes Greer

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stallergenes Greer

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arachis Hypogaea Allergen Powder-dnfp

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves Pediatric Indication Extension for Palforzia® Oral Immunotherapy

                            Details : Palforzia® is in the U.S an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.

                            Brand Name : Palforzia

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 30, 2024

                            Lead Product(s) : Arachis Hypogaea Allergen Powder-dnfp

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Stallergenes Greer

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peanut Allergen Powder-dnfp

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Nestle

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Stallergenes Greer Announces Global Agreement with Nestlé Regarding the Peanut Allergy Oral Immunotherapy Tre...

                            Details : Through the divestment, Nestle sells its peanut-allergy treatment business to stallergenes greer, including Palforzia (peanut allergen powder-dnfp), an oral immunotherapy treatment approved for the mitigation of allergic reactions, including anaphylaxis.

                            Brand Name : Palforzia

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 04, 2023

                            Lead Product(s) : Peanut Allergen Powder-dnfp

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Nestle

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Stallergenes Greer

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birch Pollen Extract

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Stallergenes Greer Initiates a European Paediatric Phase III Study With Staloral® Birch

                            Details : Staloral Staloral Birch is a sublingual solution of allergen extracts for AIT. It is indicated in the treatment of seasonal or perennial allergic rhinitis, rhino-conjunctivitis and mild to moderate allergic asthma

                            Brand Name : Staloral Birch

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2023

                            Lead Product(s) : Birch Pollen Extract

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Stallergenes Greer

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allergen Extract

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor :

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment ...

                            Details : Study results were consistent across all age groups showed a reduction of risk of asthma onset of more than 20% observed in patients undergoing treatment with sublingual liquid AIT and symptomatic drugs versus patients treated with symptomatic drugs only...

                            Brand Name : Staloral

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 02, 2022

                            Lead Product(s) : Allergen Extract

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor :

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Stallergenes Greer

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : House Dust Mite Allergen Extracts

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Stallergenes Greer Receives Market Approval in Austria for Its Sublingual Allergen Immunotherapy Tablet for Ho...

                            Details : The STAGR320 phase III clinical trial, which included 1,600 patients from 231 participating investigative sites in 13 countries, assessed the treatment of HDM-induced allergic rhinitis in adult and adolescent patients.

                            Brand Name : Actair

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 09, 2021

                            Lead Product(s) : House Dust Mite Allergen Extracts

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth